Publications by authors named "Ahmed Muteb Al-Shammeri"
Article Synopsis
- The COVID-19 pandemic has led to a push for new treatments, with molnupiravir currently in phase 3 clinical trials as a promising oral medication.
- Originally developed for influenza, molnupiravir shows efficacy against SARS-CoV-2 and is being collaborated on by Emory University, Ridgeback Biotherapeutics, and Merck.
- With a reported good safety profile and expected market availability in early 2022, molnupiravir is anticipated to fulfill the need for an effective and patient-friendly COVID-19 treatment.
